| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.42 | 2e-10 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.33 | 4e-07 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-06 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.17 | 9e-06 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-05 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.16 | 8e-05 |